Advocacy in Hemophilia: Building the Future by Design
Advances in the treatment and care of hemophilia have accelerated in recent years. And, according to Jack Uldrich, global futurist and author, the field could be on the precipice of even more disruptive changes, coming at an accelerated pace.Uldrich explains that multiple innovations could potentially advance the field. These new frontiers include gene therapy and many other novel treatment approaches, such as mobile and decentralized blood-testing technology, artificial intelligence, nanomaterials for the delivery of novel treatments, advancements in battery technology (enabling drone-blood-delivery services), synthetic b...
Source: EyeForPharma - November 3, 2022 Category: Pharmaceuticals Authors: Clare Jackson Source Type: news
Living a resilient life: The Ana Paula Carvalho story
Ana Paula ’s parents had built a picture-perfect life for their family in Mozambique. They were hard-working entrepreneurs aiming to create a bright future for their young family. But when war erupted, their lives changed in an instant. Ana Paula ’s family lost everything—their businesses, their home, their possessions—and they had no choice but to quickly flee the country for Portugal.“I was five when it happened and I still remember the chaos at the airport,” says Ana Paula.Many people from the Mozambique Colony War of Independence like Ana Paula ’s family were Portuguese, so their journey was not so much ...
Source: EyeForPharma - September 5, 2022 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news
Clinical trials: Japan ’s next chapter
Two years on from the start of the COVID-19 pandemic, and patients ’ lives have been upended. Many gave up visiting hospital even when they did not feel well. The pandemic and resulting lockdowns, terrible as they have been in so many ways, also served as a valuable testing ground for hybrid decentralized clinical trials (DCTs) in Japan. First, doctors performed medical examinations online for COVID-19 patients. Then, doctors or licensed nurses trained in good clinical practice (GCP) followed up on patients, visiting them at their homes or designated hotels.While online medical examinations during the pandemic have prov...
Source: EyeForPharma - August 31, 2022 Category: Pharmaceuticals Authors: Mary Nishikawa Source Type: news
From the Great Resignation to the Great Re-Engagement
We have all heard about the Great Resignation, through to the Great Reconsideration. It is an extraordinary trend that is shaking employers globally. Lockdowns have changed work patterns for good. Two out of every five workers have either switched jobs or are actively looking for another and remote work has become a common expectation.The Microsoft 2022 Work Trend Index, a study of more than 31,000 people in 31 countries, found that 43% of the workforce is considering leaving their jobs in the coming year. Data on LinkedIn revealed that one in seven jobs being posted in 2021 specified a remote or hybrid work component ...
Source: EyeForPharma - July 25, 2022 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
How Pharma can win back its online voice
Customer engagement now starts online. Around 80% of patients Google a recommended or newly-prescribed medication. And doctors routinely use search engines too – to stay up to date, to verify assumptions and so on.Indeed, it may be no exaggeration to say that the answers found online are possibly the biggest influence on patients and HCPs today. Understanding their real-world digital information experience is, therefore, critical to identifying the content influencing their behaviour.
But exploring what they really see and hear via search may shock you.Despite pharma ’s investment in evidence-based, balanced and a...
Source: EyeForPharma - July 5, 2022 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
How automation is changing regulatory affairs
The way pharma and regulators collaborate to bring safe new therapies to market is ripe for transformation but one major bottleneck slowing progress here is the onerous documentation process.The process of moving from paper to digital with the advent of electronic standards (eCTD) has improved certain aspects of the filing process - such as version control and the ability to copy chunks of data with greater ease – but this is only scratching the surface of what’s possible with automation. Pharma has only just begun to exploit the full potential of eCTD.A new paper from Reuters Events Pharma and DXC explores the progre...
Source: EyeForPharma - April 14, 2022 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Modularise to personalise
Digital engagement is now central to the way pharma connects with HCPs. Its urgent challenge is keeping its messaging relevant in a context in which it is consumed increasingly on social media, out of office hours, on demand and in a sea of competing content.A big part of the answer to being agile enough to compete in this demanding new environment therefore lies in putting in place chunks of pre-approved content that can be adapted to the complexities of the many different learning journeys HCPs will take.This requires a complete rethink of established content approaches that assumed linear narratives that were passively ...
Source: EyeForPharma - April 1, 2022 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Cell & Gene Therapy: High stakes and high hopes for healthcare
Revolutionary cell and gene therapies (CGT) delivering breakthrough treatments have begun to disrupt healthcare. The companies building these next-generation pharma technologies are introducing radically new operating models, influencing industry development and attracting large-scale media and investor attention. However, while growing rapidly, CGT is expected to see around just $34 billion of sales in 2030, up from $4.4 billion in 2020 compared to the global industry figure of £1.27 trillion in 2020. Although there are hundreds of CGT treatments in the pipeline, the challenges have so far kept the approved treatments ...
Source: EyeForPharma - March 29, 2022 Category: Pharmaceuticals Authors: Pamela Whitby Source Type: news
Synthetic data: pharma ’s next big thing?
Get ready for a new data technology to begin its journey through the hype cycle: synthetic data. Synthetic data will account for 60% of all data used in all AI development by 2024, according to Gartner. Facebook is getting in on the action, recently acquiring synthetic data startup AI.Reverie.Broadly applied, the term refers to ways in which data that is otherwise not available in real-world settings, or not easily available, can be created to develop new insights and solutions to real-world problems.Synthetic data offers the means to generate the missing or rare data that stymies many an AI product or RWE effort. Financ...
Source: EyeForPharma - March 22, 2022 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
FREE WEBINAR: Targeting, attention and retention: Maximise customer engagement
Channels: Access and EvidenceMedicalMultichannelPatients and MedicalClinicalColumnCommercialTags: WebinarEvent Date: Tue, 2022-03-29Event URL: https://events.reutersevents.com/pharma/personaliseengagement/utm_source=externa …Number of attendees: 700Event Organiser: Karla SharpEvent Organiser E-mail: karla.sharp@thomsonreuters.comPr écis: Find your competitive advantage through future proofed commercial objectives, data interoperability, and ROI on investmentEntire Month Duration: NoEvent Image: Audiences: MarketingCommercial (Source: EyeForPharma)
Source: EyeForPharma - March 14, 2022 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news
The rise and rise of digital budgets
The digital revolution is changing the way budgets are allocated and spent by pharma ’s commercial and medical functions in 2022 and beyond,according to new research from Reuters Events Pharma and Elsevier.The resulting report, titledThe New Era of HCP Engagement explores how the accelerating changes and fast emerging trends post-Covid in marketing, commercial, sales and medical affairs are affecting and will continue to affect budget and resource allocation in the near future.It reveals how in the promotional space, digital channels are already leading the way. And commercial spending in digital is set continue to take ...
Source: EyeForPharma - March 10, 2022 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Driven by Purpose: The Payal Sahni Story
Payal Sahni learned from her parents at a young age to “live in a way that lifts others”. If a friend was in need, it didn’t matter what they had planned—they would drop everything to help. Gratitude is another key value she lives by, such as being grateful to live in a country where the contributions of women and girls is valued. Her family fled Afghanistan for the US when she was six. Sahni, who has not returned to the home she knew, still thinks about her childhood home in Kabul, wondering if it ’s still standing and about what may have happened if her family hadn’t left. In those first months in America...
Source: EyeForPharma - February 13, 2022 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news
The future is bright for RWE in pharma approvals
Real-world evidence (RWE) could help pharma achieve many things – including understanding disease burden better and smarter monitoring of newly marketed therapies to make them safer and more effective. But the most promising near-term use case for RWE, according to a Deloitte survey of pharma executives, is in support of regulatory submissions and label expans ion. For industry stakeholders such as Marc Berger, M.D., this advance is a long time coming. The founder of the real-world data (RWD) and analytics group at Pfizer, Berger has been a contributing author on dozens of policy papers on the use of RWE – including ...
Source: EyeForPharma - January 6, 2022 Category: Pharmaceuticals Authors: Brian Eastwood Source Type: news
Accelerating the Moderna COVID-19 vaccine to commercial supply
Pr écis: Hear Paul Granadillo, SVP Global Supply at Moderna on how they accelerated the supply of their COVID-19 vaccine. This presentation took place at the Reuters Events Cell& Gene Therapy Conference in September 2021.YouTube URL: https://www.youtube.com/watch?v=LV0_knA5wE4Video Thumbnail Image: Channels: Access and EvidenceMedicalMultichannelPatients and MedicalClinicalColumnCommercial (Source: EyeForPharma)
Source: EyeForPharma - December 13, 2021 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news
Vas Narasimhan, CEO, Novartis in conversation with Axel Threlfall, Editor-at-Large, Reuters
Pr écis: This is a standalone interview between Axel Threlfall and Vas Narasimhan, not connected to any specific event. The interview took place on December 3rd. 2021.YouTube URL: https://www.youtube.com/watch?v=mu0XZVxAV3sVideo Thumbnail Image: Channels: Access and EvidenceMedicalMultichannelPatients and MedicalClinicalColumnCommercial (Source: EyeForPharma)
Source: EyeForPharma - December 13, 2021 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news
